Page 57 - JSOM Summer 2020

2. First line (INDOPACOM–SOUTHEAST ASIA): TRC-NPAV c. Initial dose = 1–2 vials, additional doses = 1 vial as needed
a. FIELD-STABLE. BROAD-SPECTRUM COVERAGE MUL- 6. First line (INDOPACOM–JAPAN/CHINA/N KOREA/S
TIPLE SPECIES OF NEURO. KOREA/VIETNAM/E RUSSIA): JSI-AYA
b. Broad-spectrum treatment option for all neurotoxic snake a. NOT FIELD-STABLE. NOT BROAD-SPECTRUM. KEEL-
envenomations by known or unknown species in Southeast BACK COVERAGE ONLY.
Asia. Best regional polyvalent. b. First line treatment option for hemotoxic and cytotoxic en-
c. Initial dose = 10 vials neurotoxic only, additional doses = 5 venomation syndromes caused by the Tiger Keelback (Rhab-
vials as needed. dophis tigrinus) and other East Asian keelback species.
3. First line (INDOPACOM–TAIWAN/SOUTHEAST c. Initial dose = 1–2 vials, additional doses = 1 vial as needed
CHINA/N LAOS/N VIETNAM): NIPM-NBB 7. First line (INDOPACOM–N KOREA/S KOREA):
a. LIQUID PRODUCT BUT FIELD-STABLE FOR SHORT KOVAX-AKA
EXCURSIONS. BROAD-SPECTRUM COVERAGE MUL- a. NOT FIELD-STABLE. NOT BROAD-SPECTRUM. KO-
TIPLE SPECIES OF NEURO. REAN MAMUSHI COVERAGE ONLY.
b. Bivalent treatment option for neurotoxic cobra and krait b. First line treatment option of hemotoxic and cytotoxic enven-
envenomations in East Asia. omation syndromes caused by the major species of Mamushi
c. Initial dose = 5 vials neurotoxic only, additional doses = 5 in the Korean Peninsula (Gloydius brevicaudus, G. ussurien-
vials as needed. sis, G. intermedius). May neutralize other related species.
4. First line (INDOPACOM–JAPAN): CSTRI-HABU c. Initial dose = 1–2 vials, additional doses = 1 vial as needed
a. NOT FIELD-STABLE. NOT BROAD-SPECTRUM. HABU 8. First line (INDOPACOM–TAIWAN/SOUTHEAST
COVERAGE ONLY. CHINA/N VIETNAM/LAOS): NIPM-SNV
b. First line treatment option for Habu envenomation (Proto- a. FREEZE-DRIED PRODUCT REQUIRING COLD CHAIN
bothrops spp.). BUT LIKELY TO BE FIELD-STABLE FOR SHORT EX-
c. Initial dose = 1–2 vials, additional doses = 1 vial as needed CURSIONS. NOT BROAD-SPECTRUM. SHARP-NOSED
5. First line (INDOPACOM–JAPAN): CSTRI-MAMU VIPER ONLY.
a. NOT FIELD-STABLE. NOT BROAD-SPECTRUM. JAPA- b. First line monovalent antivenom directly indicated for the treat-
NESE MAMUSHI COVERAGE ONLY. ment of hemotoxic and cytotoxic envenomation syndromes
b. First line treatment option for hemotoxic and cytotoxic en- caused by the sharp-nosed viper (Deinagkistrodon acutus).
venomation syndromes caused by the Japanese Mamushi c. Initial dose = 2 vials, additional doses = 1 vial as needed
(Gloydius blomhoffi).

Global Snake Envenomation Management | 55